DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của Concert Pharmaceuticals Inc

Concert Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule drugs for central nervous system disorders, genetic diseases, renal disease, inflammatory disease, and cancer. The company’s clinical-stage product candidates include AVP-786, which is in Phase II clinical trial for the treatment of neurologic and psychiatric disorders, including pain, behavioral disorders, mood disorders, and movement disorders; CTP-499 that is in Phase II clinical trial for chronic kidney disease in patients with type 2 diabetes; and CTP-354, which is in Phase I clinical trial to spasticity associated with spinal cord injury and multiple sclerosis.

TÊN CÔNG TY / COMPANY
Concert Pharmaceuticals Inc

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
CNCE

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare